# Anticoagulation For Pulmonary Hypertension in Sickle Cell Disease

> **NCT01036802** · PHASE2 · TERMINATED · sponsor: **University of North Carolina, Chapel Hill** · enrollment: 3 (actual)

## Conditions studied

- Pulmonary Hypertension

## Interventions

- **DRUG:** Warfarin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01036802
- **Lead sponsor:** University of North Carolina, Chapel Hill
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-12
- **Primary completion:** 2012-09
- **Final completion:** 2012-09
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Difficulty in accruing subjects
- **Last updated:** 2016-05-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01036802

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01036802, "Anticoagulation For Pulmonary Hypertension in Sickle Cell Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01036802. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*